Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Thymosin Alpha-1 5mg Dosage Protocol | PeptideDosages.com

Thymosin Alpha-1 (5 mg Vial) Dosage Protocol Thymosin Alpha-1 Dosage Chart Thymosin Alpha-1 is dosed at 300 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This

Thymosin Alpha-1 (5 mg Vial) Dosage Protocol

Thymosin Alpha-1 Dosage Chart

Thymosin Alpha-1 is dosed at 300 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.

Typical daily range: 300–500 mcg once daily (gradual titration).

Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate and use within 7 days.

Thymosin Alpha-1 (Tα1) is a 28–amino acid peptide originally isolated from the thymus gland, recognized for its broad immunomodulatory properties[1]. It has been investigated as an immune enhancer in chronic viral infections (hepatitis B/C, HIV/AIDS) and critical illness (sepsis, COVID-19)[2][3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Thymosin Alpha-1 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Week 1

300 mcg (0.3 mg)

18 units (0.18 mL)

Weeks 2–8

500 mcg (0.5 mg)

30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. This 8‑week protocol begins at 300 mcg to assess tolerance, then increases to a maintenance dose of 500 mcg daily from Week 2 onward. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges[4][5]. Treatment durations of 8–16 weeks are commonly reported in literature.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (Thymosin Alpha-1, 5 mg each):

8 weeks ≈ 6 vials

12 weeks ≈ 9 vials

16 weeks ≈ 12 vials

Insulin Syringes (U‑100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (6 vials): 18 mL → 2 × 10 mL bottles

12 weeks (9 vials): 27 mL → 3 × 10 mL bottles

16 weeks (12 vials): 36 mL → 4 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

16 weeks: 224 swabs → recommend 3 × 100‑count boxes

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Handling Note:

For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dissolution. *Reconstitution solutions are supplied separately. Stock: 1851 Model: Thymosin Alpha 1 5mg Molecular Formula: 62304-98-7 SKU: 5 Research Only: Yes

RESEARCH

Future research

Peptides have huge therapeutic value. Significant research has taken place over the years. It has successfully treated a wide range of diseases. It’s also used in aesthetic treatments. Many people feel comfortable in using this safe and natural approach to their health. There’s great potential for this market to increase. Investments into this area of research seem positive. Continuous support from the government and investors can increase COVID research. With the success of this treatment, there’s a need to make more of them available. Phase 3 trial in hepatitis C is still in progress. The same applies to phase 2 in hepatitis B. There are also efforts underway to improve oral availability. To make it more permeable for the GI tract.